Genmab — August 2018

[Bulder]

But is it only CLL? One could think that better affinity should be better in all kinds of tissue that expresses cd20?

[E_L]

I would agree with you on that. And upon rereading the short abstract, i also don't think they meant to restrict it to CLL only.

[E_L]

2-0 Bulder. Think EL is taking an early weekend

[Bulder]

Please don't. We cannot do without your outstanding research. The whole chat would sink deep into the shareprice debating mud.

[Legolas23]

Agree

[OHW]

Genmab Announces European Marketing Authorization for DARZALEX (daratumumab) for Front Line Multiple Myeloma

[Bulder]

For lige at vende tilbage til D-RVd fra i går. Winkel sagde på CC at vi først ville få de fulde data fra Griffin i 2019. Men desuden sagde han (fra transcr.): but there could be further data from the so-called [indiscernible] part of that study at ASH this year. er nogen der ved, hvad det er for en del?

[pauly]

Yes 1 linie godkendt

[Bulder]

Øj, det var hurtigt.

[OHW]

..men selvfølgelig allerede indregnet kursen..

[Bulder]

Så får vi maske alligevel lidt 1. linje salg i år: The sales are expected to occur quickly after the approval

[pauly]

Absolut noget der rykker selvom det ikke er på kursen .-)

[bikube]

Yes - Super - så falder kursen straks.

[Sukkeralf]

En måned før tid - great. Salget i tyskland vil ganske givet starte ret hurtigt, da de hele vejen igennem har været på forkant med Darzalex - så tre måneders salg i det største marked er ikke skidt

[Bulder]

..og Holland ikke at forglemme

[Sukkeralf]

Ja bestemt - mon NICE snart overgiver sig

[bikube]

Milstone på 13 MIO$ ved first sale. Det tager vi også med.

[bibob]

Det er vel nærmest 3 uger før tid den godkendelse kommer. Bliver spændende hvormeget det rykker på ROW i Q 4

[gentogen]

Vedrørende 12:47 (ofatumumab): https://ibj.pasteur.ac.ir/article-1-2213-en.pdf

[gentogen]

Ofatumumab Monoclonal Antibody Affinity Maturation Through in silico Modeling

Background: Ofatumumab, an anti-CD20 mAb, was approved in 2009 for the treatment of chronic lymphocytic leukemia. This mAb acts through immune-mediated mechanisms, in particular complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by natural killer cells as well as antibody-dependent phagocytosis by macrophages. Apoptosis induction is another mechanism of this antibody. Computational ...

(ibj.pasteur.ac.ir)